News Center

• Nov. 18

  2022

  CSPC Shines at CPHI Frankfurt

  The CPHI Worldwide 2022 kicked off in Frankfurt, Germany, in early November 2022.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for the World Stroke Congress (WSC) (III)

  The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.Today, we will present the third finding.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for the World Stroke Congress (WSC) (II)

  The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress. Today, we will present the second finding.

• Nov. 15

  2022

  CSPC's Three Latest Research Findings of Class 1 New Drug Selected for World Stroke Congress (WSC) (I)

  The 14th World Stroke Congress (WSC) was held in Singapore from October 26-29, 2022, by the World Stroke Organization (WSO). The three latest research findings of CSPC's class I new drug, Butylphthalide (NBP), for treating acute ischemic stroke, were selected for this Congress.

• Nov. 15

  2022

  A Subsidiary of CSPC Passes EcoVadis Social Responsibility Certification

  Recently, EcoVadis, a global corporate social responsibility (CSR) evaluation authority, completed the social responsibility audit and certification of Hebei Huarong Pharmaceutical Co., Ltd. (Huarong Pharmaceutical), a subsidiary of CSPC.

• Oct. 28

  2022

  ANTIBODY-DRUG CONJUGATE “SYS6002” OBTAINS CLINICAL TRIAL APPROVAL

  The antibody-drug conjugate “SYS6002" developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.